Ukuthunyelwa ngokuphepha CAS 1156491-10-9 (1R,2S)-rel-2-(3,4-Difluorophenyl)cyclopropanamine hydrochloride Ikhwalithi Engcono Kakhulu Intengo Ephansi Ikhwalithi Engcono Kakhulu Intengo Ephansi

I-Ticagrelor iyisidakamizwa se-antiplatelet yomlomo, igama layo lomkhiqizo waseMelika i-Brilinta, futhi igama layo le-European brand yi-Brilique. I-Ticagrelor iyi-reversible platelet adenosine diphosphate (ADP) receptor antagonist eklanyelwe ukuvimbela ama-platelet ukuba ahlangane futhi enze amahlule egazi angaholela ekuhlaselweni kwenhliziyo nokushaywa unhlangothi. E-United States, i-ticagrelor yaqala ukuvunyelwa yi-FDA ngoJulayi 2011 yokwelashwa kweziguli ezikhulile ezine-acute coronary syndrome (ACS). Idatha yomtholampilo ibonisa ukuthi i-ticagrelor iphumelela kakhulu kune-clopidogrel ekunciphiseni ukufa kwenhliziyo okungenani izinyanga ezingu-12 ngemva komcimbi we-ACS. Ukwengeza, i-ticagrelorChemicalbook iphinde yanciphisa izehlakalo ze-stent thrombosis (ST) ezigulini ezithole ama-stents ukuphatha i-ACS. NgoJuni 2020, i-AstraZeneca yamemezela ukuthi i-US Food and Drug Administration (FDA) igunyaze i-anticoagulant Brilinta (ticagrelor) ukuthi isetshenziswe ezigulini ezisengozini enkulu ye-coronary artery disease (CAD) ukunciphisa ubungozi bokuhlaselwa yinhliziyo kokuqala. noma ingozi yokushaywa unhlangothi. NgoNovemba 2020, i-AstraZeneca yamemezela ukuthi i-US Food and Drug Administration (FDA) igunyaze inkomba entsha ye-anticoagulant Brilinta (ticagrelor), ehlangene ne-aspirin, yokwelashwa kwe-ischemia eyingozi. Ezigulini ezine-hemorrhagic stroke noma ukuhlaselwa kwe-ischemic yesikhashana esiyingozi kakhulu (TIA), kunciphisa ubungozi bokushaywa unhlangothi okulandelayo.